Tergooiziekenhuizen — Clinical Trial Site

64 Registered trials

31 Currently recruiting

Organisation

Tergooiziekenhuizen

Location

Hilversum, Netherlands

Identifier

ORG-100031348

Address

Van Riebeeckweg 212, 1213 XZ, Netherlands

Departments

-
5001; Internal Medicine/Hemato-Oncology
Cardiologie
Cardiology
General Practitioner
Gynaecology
Hematology
Intensive Care
Intern Vasculair
Internal Medicine
Internal Medicine - Nephrology
Internal Medicine / Oncology
Interne Geneeskunde
Interne Oncologie
Lung department
Medical oncology
Medische Oncologie
N/A
NA
Nephrology
Neurology
Obstetrics & Gynecology
Oncology
orthopedic surgery
Pediatrics
Psychiatrie
Pulmonary Medicine
Pulmonology
Reproductive medicine and gynecology
Research Cardiologie/Wetenschapsbureau 3.F.068
Sugery
Surgery
Vascular Medicine

Clinical trials at this site (64)

Search interface

Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia (SAFE-trial) Ended

2024-515398-90-01 Staphylococcus aureus bacteremia 5 2020-08-17
Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended

2023-509287-26-00 previously untreated metastatic or locally advanced eso 4 2019-07-01
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Ended

2024-513867-19-00 metastatic Castration-Resistant Prostate Cancer (mCRPC) 5 2019-01-31
HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diff… Ended

2022-501076-26-00 high risk diffuse large B-cell lymphoma 4 2018-08-28
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Ended

2023-508606-26-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2015-04-23
Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin… Ended

2024-516202-39-00 Metastatic breast cancer 4 2013-10-10
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on… Ended

2023-509569-19-00 venous thromboembolism (VTE) 10 2022-08-10
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 5 2019-08-23
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended

2022-500413-11-00 Unresected Stage I or II Non-Small Cell Lung Cancer (NS 5 2019-06-17
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended

2024-511048-22-00 Chronic lymphocytic leukemia 4 2016-10-27
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can… Ended

2024-517856-36-00 Completely resected primary stage IB (≥ 4cm), II and II 5 2015-03-09
Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN) Ended

2024-516581-11-00 Advanced stage NSCLC 5
Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine Ended

2024-518047-37-01 Depression 6